Loading…
Loading…
CPHRF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CPHRF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CPHRF and 80,000+ other tickers.
See exactly how CPHRF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CPHRF and 80,000+ other tickers.
Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm…
Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF - Get Free Report) (TSE: CPH)'s share price passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $11.98 and traded as low as $10.00. Cipher Pharmaceuticals shares last traded at $10.19, with a volume of 9,491 shares. Cipher
Cipher Pharmaceuticals Inc. (CPH:CA) Q1 2026 Earnings Call Transcript
WASHINGTON--(BUSINESS WIRE)-- #DTP--CaryHealth, a leading digital health company, today announced the launch of its direct-to-patient (DTP) platform to support seamless access to Natroba (spinosad), a prescription treatment for head lice and scabies, in partnership with Cipher Pharmaceuticals US LLC (Cipher or Cipher Pharmaceuticals). Through this partnership, CaryHealth has designed an online custom platform to both access and quickly deliver Natroba (spinosad) to patients, which eliminates common ob.
Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF - Get Free Report) (TSE: CPH)'s share price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $11.18 and traded as high as $13.28. Cipher Pharmaceuticals shares last traded at $13.00, with a volume of 8,501 shares traded. Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. (CPH:CA) Q4 2025 Earnings Call Transcript